Cargando…

Real-World, Multicenter Case Series of Patients Treated with Isavuconazole for Invasive Fungal Disease in China

Background: The incidence of invasive fungal disease (IFD) has increased significantly, and IFD is a major cause of mortality among those with hematological malignancies. As a novel second-generation triazole antifungal drug offering both efficacy and safety, isavuconazole (ISA) is recommended by va...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Lisha, Li, Shougang, Gao, Weixi, Zhu, Xiaojian, Luo, Pan, Xu, Dong, Liu, Dong, He, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10535861/ https://www.ncbi.nlm.nih.gov/pubmed/37764073 http://dx.doi.org/10.3390/microorganisms11092229

Ejemplares similares

Isavuconazole for invasive fungal infections
Publicado: (2020)

Role of isavuconazole in the treatment of invasive fungal infections
por: Wilson, Dustin T, et al.
Publicado: (2016)

Isavuconazole Treatment for Invasive Fungal Infections in Pediatric Patients
por: Zimmermann, Philippe, et al.
Publicado: (2022)

1726. Patterns of Isavuconazole Use for Invasive Fungal Infections
por: Gow-Lee, Vanessa, et al.
Publicado: (2022)

Clinical research advances of isavuconazole in the treatment of invasive fungal diseases
por: Zhang, Tingting, et al.
Publicado: (2022)

819. Experience with Isavuconazole Use for Treatment of Invasive Fungal Infections
por: Gow-Lee, Vanessa, et al.
Publicado: (2023)

Real-World Use of Isavuconazole as Primary Therapy for Invasive Fungal Infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant
por: Dagher, Hiba, et al.
Publicado: (2022)

Comparing the Real-World Use of Isavuconazole to Other Anti-Fungal Therapy for Invasive Fungal Infections in Patients with and without Underlying Disparities: A Multi-Center Retrospective Study
por: Batista, Marjorie Vieira, et al.
Publicado: (2023)

Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections
por: Falci, Diego R, et al.
Publicado: (2013)

Isavuconazole Treatment in a Mixed Patient Cohort with Invasive Fungal Infections: Outcome, Tolerability and Clinical Implications of Isavuconazole Plasma Concentrations
por: Zurl, Christoph, et al.
Publicado: (2020)

1182. The Real-World Use of Isavuconazole as Primary or salvage Therapy of Invasive Fungal infections in High-Risk Patients with Hematologic Malignancy or Stem Cell Transplant
por: dagher, Hiba, et al.
Publicado: (2020)

Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system
por: Schwartz, Stefan, et al.
Publicado: (2020)

Real-World Use – Isavuconazole at a Large Academic Medical Center
por: Hassouna, HabiBA, et al.
Publicado: (2017)

Invasive Fungal Disease, Isavuconazole Treatment Failure, and Death in Acute Myeloid Leukemia Patients
por: Bellanger, Anne-Pauline, et al.
Publicado: (2019)

850. Real-world effectiveness and safety compared among isavuconazole, amphotericin B, and voriconazole in invasive mold disease patients
por: Qiu, Ye, et al.
Publicado: (2023)

415. Breakthrough Invasive Fungal Infections in Adult Hematologic Malignancy Patients Receiving Isavuconazole Prophylaxis
por: DeVoe, Catherine, et al.
Publicado: (2018)

2106. Evaluation of Isavuconazole for the Prophylaxis and Treatment of Invasive Fungal Infections at a Large Academic Medical Center
por: Vu, Christine, et al.
Publicado: (2019)

Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections
por: Donnelley, Monica A, et al.
Publicado: (2016)

Experience of Isavuconazole as a Salvage Therapy in Chronic Pulmonary Fungal Disease
por: Nwankwo, Lisa, et al.
Publicado: (2022)

Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations
por: Li, Julius, et al.
Publicado: (2015)

Economic Outcomes of Isavuconazole to Prevent Invasive Fungal Infection in Immunocompromised Adults: Initial Experience at an Academic Medical Center
por: Kowalewska, Christina A, et al.
Publicado: (2017)

Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial
por: Perfect, John R., et al.
Publicado: (2018)

Isavuconazole prophylaxis against invasive fungal infections in allogeneic stem cell transplantation: A single-center experience
por: Salas, Maria Queralt, et al.
Publicado: (2022)

Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response
por: Kovanda, Laura L., et al.
Publicado: (2017)

In vitro Activity of Isavuconazole and Comparators Against Clinical Isolates of Molds from a Multicenter Study in China
por: Jing, Ran, et al.
Publicado: (2022)

Isavuconazole: A Promising Salvage Therapy for Invasive Mucormycosis
por: Shafiq, Muhammad, et al.
Publicado: (2018)

Isavuconazole for COVID-19-Associated Invasive Mold Infections
por: Ullah, Nadir, et al.
Publicado: (2022)

Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)
por: Kovanda, Laura L., et al.
Publicado: (2016)

Post-hoc analysis of the safety and efficacy of isavuconazole in older patients with invasive fungal disease from the VITAL and SECURE studies
por: Hamed, Kamal, et al.
Publicado: (2023)

Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK
por: Bagshaw, Emma, et al.
Publicado: (2018)

Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens
por: Morrisette, Taylor, et al.
Publicado: (2022)

Population Pharmacokinetics and Pharmacodynamic Target Attainment of Isavuconazole against Aspergillus fumigatus and Aspergillus flavus in Adult Patients with Invasive Fungal Diseases: Should Therapeutic Drug Monitoring for Isavuconazole Be Considered as Mandatory as for the Other Mold-Active Azoles?
por: Cojutti, Pier Giorgio, et al.
Publicado: (2021)

Breaking the mold: A case of pulmonary mucormycosis treated with isavuconazole
por: Huggins, Jonathan, et al.
Publicado: (2018)

Candida Endophthalmitis Treated Successfully With Isavuconazole: A Case Report
por: Sng, Edwin Chong Yu, et al.
Publicado: (2021)

941. Isavuconazole Prophylaxis Against Invasive Fungal Infection: A Pooled Analysis with a Comparison of Posaconazole Delayed-release Tablet Prophylaxis
por: Lee, Chaeryoung, et al.
Publicado: (2021)

In Vitro Activity of Isavuconazole against Opportunistic Fungal Pathogens from Two Mycology Reference Laboratories
por: Pfaller, Michael A., et al.
Publicado: (2018)

Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study)
por: Monforte, Arnau, et al.
Publicado: (2022)

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials
por: Andes, David R., et al.
Publicado: (2018)

Isavuconazole as salvage therapy for mucormycosis
por: Graves, Bianca, et al.
Publicado: (2016)

Posaconazole and isavuconazole induced hypomagnesaemia
por: Burston, John, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_7ls2nhp4b263h67r0sh99hmel3